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Tumor associated macrophages (TAMs) in breast cancers
foster several aspects of tumor progression and metastasis,
and represent a biomarker associated with an unfavorable
clinical outcome. As new therapeutic agents selectively target-
ing leukocytes enter the clinic whose mechanism of action
involves diminishing macrophage infiltration or presence in
tumors, it becomes increasingly important to identify those
tumors heavily infiltrated by TAMs, as well as monitoring TAM
response to therapy. MR imaging with iron oxide nanoparticles
enables noninvasive quantification of TAMs in tumors, and
thus, provides an easily accessible ex vivo assessment of TAMs
for prognosis and related treatment decisions.
Experimental and clinical studies have revealed that tumor-
promoting leukocytes regulate essentially all aspects of solid tumor
development by providing a diverse assortment of soluble growth
and/or survival factors to neoplastic cells, and contribute to tissue
remodeling and angiogenesis via delivery of cytokines, potent
mediators and extracellular proteases.
1-3 Several studies have
recently demonstrated that mammary carcinomas are functionally
regulated by leukocytes, most notably both CD4
+ T cells and
monocytes/macrophages.
4-6 Moreover, we have revealed that
blocking macrophage infiltration into mammary carcinomas
significantly enhances efficacy of standard-of-care chemotherapy
and extends overall survival of tumor-prone mice.
5 These data,
derived from mouse models of mammary carcinogenesis, correlate
with human breast cancer (BC) data revealing that leukocyte
complexity predicts clinical outcome,
7 as well as response to
therapy.
5 Together, these findings indicate that identifying
patients whose BCs are heavily infiltrated with tumor-promoting
leukocytes, specifically tumor-associated macrophages (TAMs),
would most likely benefit from combining chemotherapy with
TAM-antagonist therapeutics. Thus, development of leukocyte-
selective imaging reagents will not only facilitate identification of
this patient population, but also will enable monitoring patients
during therapy.
Clinically Significant Tools for In Vivo Detection
of Macrophages in Solid Tumors
Diagnostic imaging of solid tumors has historically focused
on imaging malignant cancer cells, proteins overexpressed by
malignant cells, tumor microvascular characteristics and angio-
genic markers, or the extracellular matrix surrounding tumors,
with approaches selectively evaluating the immune component of
tumors lagging. While imaging macrophages in vivo in solid
tumors has been reported, this has been accomplished with pre-
clinical fluorophores, pre-clinical iron oxide nanoparticles for
detection by MR imaging, and other macromolecular probes for
optical imaging or fluorescence microscopy. A major limitation
with these approaches in that they have not utilized clinically-
applicable reagents; thus, we sought to develop an immediately
clinically-applicable MR imaging technique for detection of
TAMs in BC with ultrasmall superparamagnetic iron oxide
nanoparticles (USPIO).
8 To achieve this, we utilized a clinically-
applicable USPIO, and a mouse model of mammary carcino-
genesis (MMTV-PyMT) where macrophage infiltration is well
documented and functionally significant.
9
Two classes of clinically applicable iron oxide nanoparticles
for MR imaging are currently available for preclinical testing.
Superparamagnetic iron oxide nanoparticles (SPIO) have a
hydrodynamic diameter of 60–180 nm, whereas ultrasmall
SPIO (USPIO) have a diameter of 20–50 nm, both of which
have been extensively evaluated in vivo.
8-11 Intravenously injected
SPIOs are rapidly recognized and phagocytosed by macrophages
in the reticuloendothelial system (RES), and are generally too
large to traverse the endothelium of tumor microvessels in
significant quantities to allow detection with MR imaging, thus
smaller USPIOs are superior for in vivo TAM imaging. USPIO
transiently escape and delay RES-phagocytosis leading to a
prolonged blood half-life of 1–3 h and prolonged tissue perfusion.
Clinically-applicable USPIOs, such as Ferumoxytol (Feraheme,
AMAG pharmaceuticals) and P904 (Guerbet Group), do not
extravasate across intact vascular endothelia in healthy organs.
However, in tumors with increased microvascular permeability,
USPIOs gradually leak across hyperpermeable vessels into the
interstitium, where they exert a combined positive MR signal
effect on T1-weighted MR images and a negative MR signal
effect on T2-weighted MR images (Fig.1). The T1-effect is
proportional to the quantity of protons in the interstitium. In
tissues/tumors heavily infiltrated by TAMs, nanoparticles are
slowly phagocytosed by macrophages,
11 and nanoparticles retained
in TAMs in turn exert a T2-signal effect on delayed MR
scans, several hours to days after nanoparticle administration.
11
Intracellular iron oxides exert only minimal or no T1 effect due
to lack of interactions with protons.
12 This “decoupling” of T1-
and T2-signal effects can be used as a non-invasive imaging
indicator for TAM phagoctosis of the USPIO. Once within cells,
nanoparticles undergo a slow metabolization;
11 thus, baseline MR
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signal intensities of tumors and macrophage infiltrates are
regained after several days or weeks.
11
Implications for Patient Management
The ability to observe TAMs in BCs non-invasively and
longitudinally in vivo with a clinically applicable imaging reagents
would aid understanding of temporal and pathophysiological
changes of this cell population in the tumor microenvironment.
Moreover, USPIOs that detect TAMs can be applied to study the
effect of immune-response modifiers on tumoral inflammatory-
type processes by direct in vivo MR imaging. Since macrophage
density in BC correlates with clinical outcome, this information
could direct clinical decision making by stratifying patients to
individualized treatment options. For example, patients with BCs
with marked macrophage infiltration could be directed to novel
macrophage-antagonist or immune reprogramming therapies,
while patients with node-negative tumors without significant
leukocyte infiltration could be spared. USPIO-mediated TAM
imaging could also facilitate development, monitoring and
regulatory approval for new classes of immune-based drugs.
Since clinical trials of new therapeutic drugs and combination
therapies are expensive and take years to complete, the immediate
value and impact of this imaging approach could be immense.
The described TAM MR imaging technique is in principle
readily clinically applicable, could provide a new diagnostic tool to
identify patients who will benefit from intensified and anti-
inflammatory therapies, help to improve and tailor individualized
therapeutic options, and ultimately, improve long-term outcomes.
Since a generalized novel concept for tumor imaging via TAM
specific biomarkers is addressed, this imaging test might not only
be suitable for TAM imaging in BC patients but also patients with
a variety of other tumor types.
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Figure1. In vivo distribution of intravenously injected superparamagnetic iron oxide nanoparticles with resultant characteristic enhancement profiles of
vessels and tumor tissue on T1- and T2-weighted MR scans at different time points after injection.
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